Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 4;104(10):1974–1983. doi: 10.3324/haematol.2018.206540

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2019 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 4. — Outcomes after second-line therapy for relapsed/refractory disease. Kaplan-Meier analysis of (A) overall survival and (B) event-free survival for all subjects or subjects treated with horse anti-thymocyte globulin (rATG)/cyclosporine (CyA). (C) Log-rank test was used to compare event-free survival after second-line treatment with hematopoietic stem cell transplantation (HSCT) versus immunosuppressive therapy (IST) for all subjects or subjects treated with hATG/CyA.